glp-1 dementia news Can popular diabetes and weight-loss drugs slow vascular dementia? Blood Flow to Brain Function:

While earlier GLP-1 drugs have decades of data behind them, newer high-potency agonists and multi-agonist combinations will require extended monitoring as their use expands

There is no robust evidence of chronic malabsorptive syndromes attributable to GLP-1 therapy in otherwise healthy individuals

GLP-1 is a pleiotropic hormone with numerous functions besides glucose control

Treating it symptom by symptom produces, at best, partial solutions

Endocrinologists viewed their ideal patient as an individual with established cardiovascular disease or high cardiovascular risk, including those with diabetic kidney disease, who are already being treated with more than one oral medication (including either SGLT2is or GLP1-RAs) and an HbA1c level exceeding the established target

We hear all the time that our patients stopped thinking about food. GLP-1 agonists were really developed initially for the treatment of diabetes, but it became apparent pretty quickly that they can also cause weight loss, he says